Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/181697Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Hueso Val, Miguel | - |
| dc.contributor.author | Mallén, Adrián | - |
| dc.contributor.author | Suñé Pou, Marc | - |
| dc.contributor.author | Aran Perramon, Josep M. | - |
| dc.contributor.author | Suñé i Negre, Josep M. (Josep Maria) | - |
| dc.contributor.author | Navarro, Estanis | - |
| dc.date.accessioned | 2021-12-09T08:43:34Z | - |
| dc.date.available | 2021-12-09T08:43:34Z | - |
| dc.date.issued | 2021-10-27 | - |
| dc.identifier.issn | 1422-0067 | - |
| dc.identifier.uri | http://hdl.handle.net/2445/181697 | - |
| dc.description.abstract | Non-coding RNAs (ncRNAs) are emerging therapeutic tools but there are barriers to their translation to clinical practice. Key issues concern the specificity of the targets, the delivery of the molecules, and their stability, while avoiding "on-target" and "off-target" side effects. In this "ncRNA in therapeutics" issue, we collect several studies of the differential expression of ncRNAs in cardiovascular diseases, bone metabolism-related disorders, neurology, and oncology, and their potential to be used as biomarkers or therapeutic targets. Moreover, we review recent advances in the use of antisense ncRNAs in targeted therapies with a particular emphasis on their basic biological mechanisms, their translational potential, and future trends. | - |
| dc.format.extent | 15 p. | - |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | eng | - |
| dc.publisher | MDPI AG | - |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ijms222111596 | - |
| dc.relation.ispartof | International Journal of Molecular Sciences, 2021, vol. 22, num. 21, p. 11596 | - |
| dc.relation.uri | https://doi.org/10.3390/ijms222111596 | - |
| dc.rights | cc by (c) Hueso Val, Miguel et al, 2021 | - |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
| dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | - |
| dc.subject.classification | Nanomedicina | - |
| dc.subject.classification | Àcids nucleics | - |
| dc.subject.other | Nanomedicine | - |
| dc.subject.other | Nucleic acids | - |
| dc.title | NcRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/publishedVersion | - |
| dc.identifier.idgrec | 718189 | - |
| dc.date.updated | 2021-12-02T08:29:25Z | - |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
| dc.identifier.pmid | 34769025 | - |
| Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| ijms-22-11596-v2.pdf | 6.68 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
